Cargando…
ARF-BP1 as a potential therapeutic target
In this review, we discuss the recent identification of ARF-BP1 (also known as Mule, UREB1, E3(histone), LASU1, and HectH9). ARF-BP1, a HECT domain-containing E3 ubiquitin ligase, interacts with ARF and p53. Its ubiquitin ligase activity is inhibited by ARF. Inactivation of ARF-BP1 stabilised p53 an...
Autores principales: | Chen, D, Brooks, C L, Gu, W |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361317/ https://www.ncbi.nlm.nih.gov/pubmed/16641901 http://dx.doi.org/10.1038/sj.bjc.6603119 |
Ejemplares similares
-
Regulatory Network of ARF in Cancer Development
por: Ko, Aram, et al.
Publicado: (2018) -
TMPRSS4: an emerging potential therapeutic target in cancer
por: de Aberasturi, A L, et al.
Publicado: (2015) -
Protease-activated receptor 1 as a potential therapeutic target for COVID-19
por: Rovai, Emanuel S., et al.
Publicado: (2020) -
RON in hepatobiliary and pancreatic cancers: Pathogenesis and potential therapeutic targets
por: Chen, Shao-Long, et al.
Publicado: (2021) -
Oncogenic AKTivation of translation as a therapeutic target
por: Hsieh, A C, et al.
Publicado: (2011)